|Articles|July 27, 2006

FDA Extends CRADA with EduNeering for Inspection Training

EduNeering (Princeton, NJ, www.eduneering.com) and the Food and Drug Administration (Washington, DC, www.fda.gov) have extended their existing Cooperative Research and Developing Agreement (CRADA), originally formed in 1999, for five more years.

EduNeering (Princeton, NJ, www.eduneering.com) and the Food and Drug Administration (Washington, DC, www.fda.gov) have extended their existing Cooperative Research and Developing Agreement (CRADA), originally formed in 1999, for five more years. The original agreement was the first such CRADA formed between FDA and a private sector company. EduNeering’s ComplianceWire technology developed the Office of Regulatory Affairs’ virtual university (ORA U) to help train local, state, and federal regulators in a variety of subjects, including inspections, using course material supplied by the agency. The extension will expand learning solutions available for FDA employees and clients through new technologies developed since the original agreement was formed, including a virtual audit, which will allow users to “walk-through” their facilities and identify any potential problem areas or possible violations.


Related to this article

The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.